Physician profile
Stanton Carl Goldman
NPI 1295778843
$233,866.15
in general payments reported to CMS, 2019-2025
17 companies · $25K in 2025
The $25K reported for 2025 was more than what 93% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $6,652 · 2021: $22K · 2022: $18K · 2023: $57K · 2024: $85K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Travel and Lodging: $17K · Food and Beverage: $3,218 · Consulting Fee: $3,180 · Education: $83.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,538.00 |
| Travel and Lodging | $17,256.84 |
| Food and Beverage | $3,218.35 |
| Consulting Fee | $3,180.00 |
| Education | $83.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $232,480.09 | 2019-2025 | |
| Genzyme Corporation | $318.23 | 2020-2024 | |
| Sobi, INC | $238.78 | 2023 | |
| Astellas Pharma US INC | $208.44 | 2024-2025 | Cresemba |
| Servier Pharmaceuticals LLC | $187.06 | 2022 | |
| Genentech, INC. | $149.85 | 2021 | |
| Pfizer INC. | $99.05 | 2020-2024 | |
| Alexion Pharmaceuticals, INC. | $45.48 | 2022-2023 | Koselugo |
| Takeda Pharmaceuticals U.S.A., INC. | $26.90 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $26.21 | 2023 | Imbruvica |
| Genentech USA, INC. | $25.04 | 2019 | |
| Merck Sharp & Dohme LLC | $22.90 | 2025 | Prevymis |
| Uswm, LLC | $22.22 | 2024 | Iwilfin |
| Fennec Pharmaceuticals, INC. | $15.90 | 2024 | Pedmark |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanton Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.